Your browser doesn't support javascript.
loading
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Garcia, Jacqueline S; Flamand, Yael; Penter, Livius; Keng, Michael; Tomlinson, Benjamin K; Mendez, Lourdes M; Koller, Paul; Cullen, Nicole; Arihara, Yohei; Pfaff, Kathleen; Wolff, Jacquelyn O; Brunner, Andrew M; Galinsky, Ilene; Bashey, Asad; Antin, Joseph H; Cutler, Corey; Ho, Vincent; Jonas, Brian A; Luskin, Marlise R; Wadleigh, Martha; Winer, Eric S; Savell, Alexandra; Leonard, Rebecca; Robertson, Taylor; Davids, Matthew S; Streicher, Howard; Rodig, Scott J; Ritz, Jerome; Wu, Catherine J; DeAngelo, Daniel J; Neuberg, Donna; Stone, Richard M; Soiffer, Robert J.
Afiliação
  • Garcia JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Flamand Y; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Penter L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Keng M; Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.
  • Tomlinson BK; Department of Hematology/Oncology, Case Comprehensive Cancer Center, Cleveland, OH.
  • Mendez LM; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA.
  • Koller P; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
  • Cullen N; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Arihara Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Pfaff K; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Wolff JO; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Brunner AM; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.
  • Galinsky I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Bashey A; The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA.
  • Antin JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Cutler C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Ho V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Jonas BA; Division of Cellular Therapy, BMT and Malignant Hematology, University of California, Davis, Sacramento, CA.
  • Luskin MR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Wadleigh M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Winer ES; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Savell A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Leonard R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Robertson T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Streicher H; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.
  • Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA.
  • Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • DeAngelo DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Neuberg D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Soiffer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Blood ; 141(15): 1884-1888, 2023 04 13.
Article em En | MEDLINE | ID: mdl-36332187

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article